Archive · 26 Dec 2025
Sun Pharma Recalls Antifungal Shampoo in US
Sun Pharma's company, Taro, is recalling over 17,000 units of an antifungal shampoo in the US.
The shampoo, called Ciclopirox, is used to treat a skin condition that causes dry, flaky, and itchy skin.
The recall is happening because the shampoo didn't meet certain quality standards.
The recall is a Class II, which means it might cause temporary health problems but not serious ones.
Sun Pharma completed a merger with Taro last year, making Taro a private company owned by Sun Pharma.
Indian pharmaceutical companies, like Sun Pharma, supply a lot of medicines to the US.
Sun Pharma is a big company in India and sells many medicines in the US, but their sales in the US went down a bit recently.
Taro Pharmaceutical Industries, a Sun Pharma unit, is recalling 17,664 units of Ciclopirox Shampoo in the US.
The recall is due to 'Failed Impurity/Degradation specifications' according to the USFDA.
The shampoo treats seborrheic dermatitis, a condition causing dry, flaky, and itchy skin.
The recall was initiated on December 9, 2025, and is classified as Class II.
Sun Pharma completed the merger with Taro in 2024, making Taro a private company wholly owned by Sun Pharma.
- Who
- Taro Pharmaceutical Industries, a unit of Sun Pharma
- What
- Recall of Ciclopirox Shampoo due to manufacturing issues
- When
- Recall initiated on December 9, 2025
- Where
- United States
- Why
- Failed Impurity/Degradation specifications
Sun Pharma
USFDA
Recall Classification
Sun Pharma
Class II recall indicating temporary health consequences
USFDA
Class II recall with minimal likelihood of serious adverse health outcomes
- Company
- Taro Pharmaceutical Industries (Sun Pharma arm)
- Product
- Ciclopirox Shampoo
- Units Recalled
- 17,664
- Reason
- Failed Impurity/Degradation specifications
- Recall Class
- Class II
- Recall Date
- December 9, 2025
- Condition Treated
- Seborrheic dermatitis
- Merger Value
- $347.73 million
- Sun Pharma's US Revenue (Q2 FY26)
- Rs 14,478 crore
- Sun Pharma's Net Profit (Q2 FY26)
- Rs 3,118 crore
- Formulation Sales in US (Q2 FY26)
- $496 million
